A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

A 24 Week, Randomised, Assessor Blinded, Active-controlled, Parallel Group, Phase 3, 2 Arm Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life.

The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.

Study Overview

• Status: Completed
• Conditions: Chronic Hand Eczema
• Intervention / Treatment: Drug: Delgocitinib; Drug: Toctino

• Study Type: Interventional
• Enrollment (Actual): 513
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Clinical Disclosure; Phone Number: (+1) 877-557-1168; Email: clinicaltrialscontactus@leo-pharma.com

Study Locations

• Austria
  • Graz, Austria, 8036
    • LEO Pharma Investigational Site
  • Linz, Austria, 4021
    • LEO Pharma Investigational Site
  • Linz, Austria, 4010
    • LEO Pharma Investigational Site
• Canada
  • Calgary, Canada, T2J 7E1
    • LEO Pharma Investigational Site
  • Calgary, Canada, T2W 4X9
    • LEO Pharma Investigational Site
  • Edmonton, Canada, T6G 1C3
    • LEO Pharma Investigational Site
  • Edmonton, Canada, T6W0J5
    • LEO Pharma Investigational Site
  • Guelph, Canada, N1L 0B7
    • LEO Pharma Investigational Site
  • London, Canada, N6A 2C2
    • LEO Pharma Investigational Site
  • London, Canada, N6A 5R9
    • LEO Pharma Investigational Site
  • Markham, Canada, L3P 1X3
    • LEO Pharma Investigational Site
  • Niagara Falls, Canada, L2H 1H5
    • LEO Pharma Investigational Site
  • North York, Canada, M2N 3A6
    • LEO Pharma Investigational Site
  • Québec, Canada, G1W 4R4
    • LEO Pharma Investigational Site
  • Red Deer, Canada, T4P 1K4
    • LEO Pharma Investigational Site
  • Sherbrooke, Canada, J1G 1X9
    • LEO Pharma Investigational Site
• France
  • Antony, France, 92160
    • LEO Pharma Investigational Site
  • Martigues, France, 13500
    • LEO Pharma Investigational Site
  • Montpellier, France, 34295
    • LEO Pharma Investigational Site
  • Nice, France, 06000
    • LEO Pharma Investigational Site
  • Nice, France, 6202
    • LEO Pharma Investigational Site
  • Reims, France, 51100
    • LEO Pharma Investigational Site
  • Toulon, France, 83000
    • LEO Pharma Investigational Site
• Germany
  • Augsburg, Germany, 86163
    • LEO Pharma Investigational Site
  • Berlin, Germany, 10789
    • LEO Pharma Investigational Site
  • Berlin, Germany, 13055
    • LEO Pharma Investigational Site
  • Bochum, Germany, 44791
    • LEO Pharma Investigational Site
  • Bochum, Germany, 44793
    • LEO Pharma Investigational Site
  • Bonn, Germany, 53111
    • LEO Pharma Investigational Site
  • Darmstadt, Germany, 64283
    • LEO Pharma Investigational Site
  • Dresden, Germany, 01307
    • LEO Pharma Investigational Site
  • Erlangen, Germany, 91054
    • LEO Pharma Investigational Site
  • Essen, Germany, 45147
    • LEO Pharma Investigational Site
  • Frankfurt, Germany, 60590
    • LEO Pharma Investigational Site
  • Friedrichshafen, Germany, 88045
    • LEO Pharma Investigational Site
  • Gera, Germany, 07548
    • LEO Pharma Investigational Site
  • Göttingen, Germany, 37075
    • LEO Pharma Investigational Site
  • Halle, Germany, 06110
    • LEO Pharma Investigational Site
  • Hamburg, Germany, 22391
    • LEO Pharma Investigational Site
  • Heidelberg, Germany, 69120
    • LEO Pharma Investigational Site
  • Langenau, Germany, 89129
    • LEO Pharma Investigational Site
  • Lohne, Germany, 49393
    • LEO Pharma Investigational Site
  • Mainz, Germany, 55131
    • LEO Pharma Investigational Site
  • Marburg, Germany, 35043
    • LEO Pharma Investigational Site
  • Memmingen, Germany, 87700
    • LEO Pharma Investigational Site
  • München, Germany, 80337
    • LEO Pharma Investigational Site
  • München, Germany, 80802
    • LEO Pharma Investigational Site
  • Oldenburg, Germany, 26133
    • LEO Pharma Investigational Site
  • Osnabrück, Germany, 49074
    • LEO Pharma Investigational Site
  • Wuppertal, Germany, 42287
    • LEO Pharma Investigational Site
• Italy
  • Bologna, Italy, 40138
    • LEO Pharma Investigational Site
  • Brescia, Italy, 25123
    • LEO Pharma Investigational Site
  • Catania, Italy, 95123
    • LEO Pharma Investigational Site
  • Catanzaro, Italy, 88100
    • LEO Pharma Investigational Site
  • Genova, Italy, 16132
    • LEO Pharma Investigational Site
  • Lucca, Italy, 55100
    • LEO Pharma Investigational Site
  • Milano, Italy, 20089
    • LEO Pharma Investigational Site
  • Pavia, Italy, 27100
    • LEO Pharma Investigational Site
  • Pisa, Italy, 56126
    • LEO Pharma Investigational Site
  • Terracina, Italy, 4019
    • LEO Pharma Investigational Site
• Norway
  • Stavanger, Norway, 4011
    • LEO Pharma Investigational Site
  • Tromsø, Norway, 9038
    • LEO Pharma Investigational Site
• Poland
  • Białystok, Poland, 15-794
    • LEO Pharma Investigational Site
  • Bydgoszcz, Poland, 85-796
    • LEO Pharma Investigational Site
  • Chorzów, Poland, 41-500
    • LEO Pharma Investigational Site
  • Gdańsk, Poland, 80-546
    • LEO Pharma Investigational Site
  • Gdynia, Poland, 81-338
    • LEO Pharma Investigational Site
  • Katowice, Poland, 40-081
    • LEO Pharma Investigational Site
  • Katowice, Poland, 40-611
    • LEO Pharma Investigational Site
  • Katowice, Poland, 40-851
    • LEO Pharma Investigational Site
  • Kraków, Poland, 30-033
    • LEO Pharma Investigational Site
  • Kraków, Poland, 31-501
    • LEO Pharma Investigational Site
  • Kraków, Poland, 30-727
    • LEO Pharma Investigational Site
  • Lublin, Poland, 20-080
    • LEO Pharma Investigational Site
  • Poznań, Poland, 61-731
    • LEO Pharma Investigational Site
  • Strzelce Opolskie, Poland, 47-100
    • LEO Pharma Investigational Site
  • Szczecin, Poland, 71-434
    • LEO Pharma Investigational Site
  • Warszawa, Poland, 02-677
    • LEO Pharma Investigational Site
  • Wrocław, Poland, 51-685
    • LEO Pharma Investigational Site
  • Łódź, Poland, 90-436
    • LEO Pharma Investigational Site
• Slovakia
  • Bratislava, Slovakia, 851 01
    • LEO Pharma Investigational Site
  • Svidník, Slovakia, 089 01
    • LEO Pharma Investigational Site
  • Trnava, Slovakia, 917 75
    • LEO Pharma Investigational Site
• Spain
  • Alcalá de Henares, Spain, 28805
    • LEO Pharma Investigational Site
  • Alicante, Spain, 03010
    • LEO Pharma Investigational Site
  • Badalona, Spain, 08916
    • LEO Pharma Investigational Site
  • Barcelona, Spain, 08003
    • LEO Pharma Investigational Site
  • Barcelona, Spain, 08025
    • LEO Pharma Investigational Site
  • Córdoba, Spain, 14004
    • LEO Pharma Investigational Site
  • Hospitalet de Llobregat, Spain, 08907
    • LEO Pharma Investigational Site
  • Madrid, Spain, 28006
    • LEO Pharma Investigational Site
  • Madrid, Spain, 28041
    • LEO Pharma Investigational Site
  • Madrid, Spain, 28034
    • LEO Pharma Investigational Site
  • Madrid, Spain, 28040
    • LEO Pharma Investigational Site
  • Málaga, Spain, 29009
    • LEO Pharma Investigational Site
  • Pontevedra, Spain, 36071
    • LEO Pharma Investigational Site
  • Sevilla, Spain, 41009
    • LEO Pharma Investigational Site
  • Valencia, Spain, 46014
    • LEO Pharma Investigational Site
  • Valencia, Spain, 46026
    • LEO Pharma Investigational Site
  • Zaragoza, Spain, 50009
    • LEO Pharma Investigational Site
• United Kingdom
  • London, United Kingdom, SE1 9RT
    • LEO Pharma Investigational Site
  • Nottingham, United Kingdom, NG7 2UH
    • LEO Pharma Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Main inclusion criteria:

• Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
• Disease severity graded as severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 4).
• Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
• Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
• Participants must use contraceptive methods in accordance with local regulations regarding the methods of contraception for those participating in clinical studies

Main exclusion criteria:

• Concurrent skin diseases on the hands, e.g. tinea manuum.
• Active atopic dermatitis requiring medical treatment in regions other than the hands and feet.
• Active psoriasis on any part of the body.
• Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
• Clinically significant infection on the hands.
• Participants who cannot receive alitretinoin.
• Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial.
• History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.

• Any disorder which is not stable and could:

  • Affect the safety of the participant throughout the trial.
  • Impede the participant's ability to complete the trial.
• Positive hepatitis B surface antigen or hepatitis C virus antibody serology at screening.
• Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline.
• Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline.
• Previous or current treatment with Janus kinase (JAK) inhibitors (including delgocitinib/LEO 124249), systemic or topical.
• Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline.
• Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
• Other transdermal or cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline.
• Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.

• Treatment with any marketed biological therapy or investigational biologic agents:

  • Any cell-depleting agents: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
  • Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
• Previously used alitretinoin or participated in a clinical trial with alitretinoin or delgocitinib.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Delgocitinib cream 20 mg/g; Twice-daily topical application for up to 24 weeks	Drug: Delgocitinib; Cream for topical application 20 mg/g
Active Comparator: Alitretinoin capsules 30 mg per capsule; 1 capsule per day for up to 24 weeks	Drug: Toctino; 1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in HECSI score from baseline to Week 12	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HECSI-90 at Week 12	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.	12 weeks
IGA-CHE TS at Week 12.	The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.	12 weeks
Change in HESD itch score (weekly average) from baseline to Week 12	The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.	12 weeks
Change in HESD pain score (weekly average) from baseline to Week 12.	The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.	12 weeks
AUC of HECSI-90 from baseline up to Week 24	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.	24 weeks
AUC of change from baseline in DLQI score up to Week 24	The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30). The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated piecewise from Week 0 to Week 24. Differences will be analysed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.	24 weeks
Change in HECSI score from baseline to Week 24	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).	24 weeks
Number of treatment-emergent AEs from baseline up to Week 26	An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.	26 weeks
Number of treatment-emergent SAEs from baseline up to Week 26	A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.	26 weeks
Number of AEs leading to IMP discontinuation up to Week 24	The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).	24 weeks

Collaborators and Investigators

• Sponsor: LEO Pharma
• Investigators: Study Director: Medical Expert, LEO Pharma

Study record dates

Study Major Dates

• Study Start (Actual): June 15, 2022
• Primary Completion (Actual): November 8, 2023
• Study Completion (Actual): December 5, 2023

Study Registration Dates

• First Submitted: February 18, 2022
• First Submitted That Met QC Criteria: February 18, 2022
• First Posted (Actual): February 28, 2022

Study Record Updates

• Last Update Posted (Actual): April 9, 2024
• Last Update Submitted That Met QC Criteria: April 8, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Dermatitis; Skin Diseases, Eczematous; Eczema; Antineoplastic Agents; Dermatologic Agents; Alitretinoin
• Other Study ID Numbers: LP0133-1528; 2021-003543-16 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified IPD can be made available to researchers in a closed environment for a specified period of time.
• IPD Sharing Time Frame: Data is available to request after results of the trial are available on leopharmatrials.com
• IPD Sharing Access Criteria: Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No